- Home
- DSM vs ATLN Comparison
DSM vs ATLN Comparison
Compare DSM & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- ATLN
- Stock Information
- Founded
- DSM 1989
- ATLN 2014
- Country
- DSM United States
- ATLN United States
- Employees
- DSM N/A
- ATLN N/A
- Industry
- DSM Investment Managers
- ATLN
- Sector
- DSM Finance
- ATLN
- Exchange
- DSM Nasdaq
- ATLN NYSE
- Market Cap
- DSM 301.0M
- ATLN 269.5M
- IPO Year
- DSM N/A
- ATLN 2021
- Fundamental
- Price
- DSM $5.86
- ATLN $3.53
- Analyst Decision
- DSM
- ATLN
- Analyst Count
- DSM 0
- ATLN 0
- Target Price
- DSM N/A
- ATLN N/A
- AVG Volume (30 Days)
- DSM 161.7K
- ATLN 32.2K
- Earning Date
- DSM 01-01-0001
- ATLN 01-01-0001
- Dividend Yield
- DSM 3.97%
- ATLN N/A
- EPS Growth
- DSM N/A
- ATLN N/A
- EPS
- DSM N/A
- ATLN N/A
- Revenue
- DSM N/A
- ATLN $429,260,149.00
- Revenue This Year
- DSM N/A
- ATLN N/A
- Revenue Next Year
- DSM N/A
- ATLN N/A
- P/E Ratio
- DSM N/A
- ATLN N/A
- Revenue Growth
- DSM N/A
- ATLN 5.50
- 52 Week Low
- DSM $4.69
- ATLN $1.30
- 52 Week High
- DSM $6.05
- ATLN $8.98
- Technical
- Relative Strength Index (RSI)
- DSM 47.31
- ATLN N/A
- Support Level
- DSM $5.79
- ATLN N/A
- Resistance Level
- DSM $5.86
- ATLN N/A
- Average True Range (ATR)
- DSM 0.05
- ATLN 0.00
- MACD
- DSM 0.01
- ATLN 0.00
- Stochastic Oscillator
- DSM 70.53
- ATLN 0.00
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.